Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

Launched by MSD ITALIA S.R.L. · Jan 7, 2025

Keywords

ClinConnect Summary

This clinical trial is a study that looks at the characteristics and treatment of cervical cancer in women in Italy. It focuses on patients who have locally advanced, recurrent, or metastatic cervical cancer, meaning their cancer has either spread beyond its original site or has come back after treatment. The study reviews medical records from patients who received care at oncologic clinics between January 2018 and December 2021. The goal is to gather information that can help understand how these types of cervical cancer are treated and managed.

To participate in this study, women must be at least 18 years old and have a diagnosis of cervical cancer that is not suitable for surgery or has come back after treatment. Participants also need to have received treatment for their advanced cancer during the specified time frame. However, those currently involved in other drug trials or who have received certain specific medications are not eligible. If you join the study, your medical history will be reviewed, but you will not need to undergo any special procedures or treatments just for this research. This study aims to enhance understanding of cervical cancer and improve future care for patients like you.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF)
• • Age ≥18 years
• • Diagnosis of a cervical cancer
• • Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease
• • Any treatment received between January 2018 and December 2021 for advanced disease
• Exclusion Criteria:
• • Patients participating in a pharmacological clinical trial for the treatment of advanced disease
• • Patients who participated in a clinical trial
• • Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs